drugset / Trial / NCT02283840
Single Dose Crossover Comparative Bioavailability Study of Eslicarbazepine Acetate Versus To-be-marketed Formulation
RandomizedCrossoverSingle-blindTreatment
Summary
Single center, randomized, single dose, laboratory-blinded, 2-period, 2-sequence, crossover design
Timeline
- Start
- 2007-05
- Primary completion
- 2007-06
- Completion
- 2007-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Eslicarbazepine acetate | Unknown | 400 mg | Oral |
| Subject | Eslicarbazepine acetate | Unknown | 600 mg | Oral |
| Subject | Eslicarbazepine acetate | Unknown | 800 mg | Oral |